Metabolic Side-Effects of Estrogen Therapy for Prostatic Cancer

REFERENCES

• Aro J, Haapiainen R, Rasi V, Rannikko S, Alfthan O. The effect of parenteral estrogen versus orchiectomy on blood coagulation and fibrinolysis in prostatic cancer patients. Eur Urol 1990; 17: 161.
   PubMed Web of Science ®Google Scholar
• Aro J, Haapiainen R, Sane T, Rannikko S, Pelkonen R, Alfthan O. Effects of orchiectomy and polyestradiol phosphate therapy on serum lipoprotein lipids and glucose tolerance. Eur Urol 1990; 17: 229.
   PubMed Web of Science ®Google Scholar
• Bailar JC, Byar DP and The Veterans Administration Co—operative Research Group. Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo. Cancer 1979; 26: 257.
   Google Scholar
• Buller HR, Boon TA, Henry CP, Dabhoiwala NF, Cate JW. Estrogen—induced deficiency and decrease in antithrombin III activity in patients with prostatic cancer. J Urol 1982; 44: 783.
   Google Scholar
• Carlström K, Collste L, Eriksson A, Henriksson P, Pousette A, Siege R, V. Shoultz B. A comparison of androgen status in patients with prostatic cancer treated with oral and/or parenteral estrogens or by orchiectomy. Prostate 1989; 14: 177.
   PubMed Web of Science ®Google Scholar
• Clinch J, Tindall VR. Hepatic dysfunction caused by oral contraceptives. Brit Med J 1969; 1: 602.
   PubMedGoogle Scholar
• Gustafsson A, Nilsson S, Persson B, Tisell L—E, Wiklund O, Ohlson R. Treatment with oral estramustine phosphate (Estracyt) in prostatic carcinoma. Influences on lipid and carbohydrate metabolism. Invest Urol 1977; 15: 220.
   PubMedGoogle Scholar
• Hedlund PO, Gustavson H, Sjögren S. Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) and conventional estrogen. A follow—up of 212 randomized patients. Scand J Urol Nephrol 1980, suppl 55, p. 103.
   Google Scholar
• Henriksson P, Blombäck M, Bratt G, Edhag O, Eriksson A. Activators and inhibitors of coagulation and fibrinolysis in patients with prostatic cancer treated with estrogen or orchiectomy. Thromb Res 1986; 44: 783.
   PubMed Web of Science ®Google Scholar
• Henriksson P, Einarsson K, Eriksson A, Kelter U, Angelin B. Estrogen induced gallstone formation in males. Relation to changes in serum and biliary lipids during hormonal treatment of prostatic carcinoma. J Clin Invest 1989; 84: 811.
   PubMed Web of Science ®Google Scholar
• Henriksson P, Blombäck M, Eriksson A, Stege R, Carlström K. Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Brit J Urol 1990; 65: 282.
   PubMedGoogle Scholar
• Kontturi M, Sotaniemi E. Effect of oestrogen on liver function of prostatic cancer patients. Brit Med J 1969; 4: 204.
   PubMedGoogle Scholar
• Kontturi M, Sotaniemi E. Effect of estrogen on the serum cholesterol and triglyceride levels of prostatic cancer patients. J Urol 1971; 105: 847.
   PubMed Web of Science ®Google Scholar
• Kontturi M, Sotaniemi E. Thromboembolism during estrogen therapy of prostatic cancer. Scand J Urol Nephrol 1971; 5: 108.
   PubMedGoogle Scholar
• Kontturi M, Sotaniemi E, Ahlqvist J. Liver damage and estrogen therapy of prostatic cancer. Scand J Urol Nephrol 1972; 6: 289.
   PubMed Web of Science ®Google Scholar
• Kontturi M, Sotaniemi E, Larmi TKI. Body fluid and electrolyte balance during estrogen therapy of prostatic cancer. J Urol 1974; 111: 652.
   PubMedGoogle Scholar
• Kontturi M, Sotaniemi E. Prevention of body fluid retention by furosemide during estrogen therapy of prostatic cancer. J Urol 1975; 114: 251.
   PubMedGoogle Scholar
• Kontturi M, Lukkarinen O. Serum testosterone, haematological parameters and serum lipids during gosereline and polyestradiol treatment in patients with advanced prostatic cancer. Finnish Urological Club 1989; p. 31.
   Google Scholar
• Rössner S, Hedlund PO, Jogestrand T, Säve U. Treatment of prostatic cancer. Effects on serum lipoproteins and the cardiovascular complications. J Urol 1985; 133: 53.
   PubMed Web of Science ®Google Scholar
• von Schoultz B, Carlstrom K, Collste L, Eriksson A. Henriksson P, Pousette A, Stege R. Estrogen therapy and liver function. Metabolic effects of oral and parenteral administration. Prostate 1989; 14: 389.
   PubMed Web of Science ®Google Scholar
• Shahmanesh M, Bolton Ch, Feneley RCL, Hartog M. Metabolic effects of oestrogen treatment in patients with carcinoma of prostate: A comparison of stilbestrol and conjugated equine oestrogens. Brit Med J 1973; 2: 512.
   PubMedGoogle Scholar
• Sotaniemi EA, Kontturi MJ, Larmi TKI. Effect of diaethylstilbestrol on blood glucose of prostatic cancer patients. Invest Urol 1973; 10: 438.
   PubMedGoogle Scholar
• Sotaniemi E, Kontturi M. Serum lipid levels and thromboembolic complications during estrogen therapy of prostatic cancer. Scand J Urol Nephrol 1975; 9: 89.
   PubMed Web of Science ®Google Scholar
• Stege R, Frohlander N, Carlström K, Pousette A, von Schoultz B. Steroid—sensitive proteins, growth hormone and somatomedin C in prostatic cancer: effects of parenteral and oral estrogen therapy, Prostate 1987; 10: 333.
   Google Scholar
• Wallentin L, Varenhorst E. Plasma lipoproteins during anti—androgen treatment by estrogens or orchiectomy in men with prostatic carcinoma. Horm Metab Res 1981; 13: 293.
   PubMedGoogle Scholar
• Varenhorst E, Wallentin L, Risberg B. The effect of orchiectomy, estrogens, and cyproterone acetate on the antithrombin III concentration in carcinoma of the prostate. Urol Res 1981; 9: 25.
   PubMedGoogle Scholar
• Veterans Administration Co—operative Urological Research Group 1967. Treatment and survival of patients with cancer of the prostate. Surg Gynec Obstet 1967; 124: 1011.
   PubMedGoogle Scholar